MyliconGas 40mg 50 chewable tablets

MyliconGas 40mg 50 chewable tablets is a drug specifically formulated for the symptomatic treatment of gastrointestinal meteorism and aerophagia in adults. Each tablet contains simethicone (activated dimethylpolysiloxane) as the active ingredient, known for its effectiveness in reducing the accumulation of gas in the gastrointestinal tract. The tablets are designed to be chewed, thus facilitating rapid relief from symptoms associated with abdominal bloating. The formulation also includes excipients such as lactose and sodium , which contribute to the stability and effectiveness of the product. MyliconGas is a practical and convenient solution for those looking for an effective remedy against disorders related to excess intestinal gas.

ACTIVE INGREDIENTS

Active ingredients contained in MyliconGas 40mg 50 chewable tablets - What is the active ingredient in MyliconGas 40mg 50 chewable tablets?

Each tablet contains: Active ingredient : simethicone (activated dimethylpolysiloxane) 40 mg. Excipient with known effect: Lactose, sodium. For the full list of excipients, see 6.1

EXCIPIENTS

Composition of MyliconGas 40mg 50 chewable tablets - What does MyliconGas 40mg 50 chewable tablets contain?

Saccharin; alginic acid; lactose ; sodium bicarbonate; povidone; calcium silicate hydrate; magnesium stearate.

DIRECTIONS

Therapeutic indications MyliconGas 40mg 50 chewable tablets - Why is MyliconGas 40mg 50 chewable tablets used? What is it used for?

Symptomatic treatment of gastrointestinal meteorism and aerophagia in adults.

CONTRAINDICATIONS SIDE EFFECTS

Contraindications MyliconGas 40mg 50 chewable tablets - When should MyliconGas 40mg 50 chewable tablets not be used?

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

DOSAGE

Quantity and method of taking MyliconGas 40mg 50 chewable tablets - How to take MyliconGas 40mg 50 chewable tablets?

Dosage Adults : 4 tablets per day. Do not exceed the recommended dose. After a short period of treatment without appreciable results, consult your doctor. Paediatric population Mylicongas is not suitable for paediatric use. Method of administration Take 2 tablets at the end of each main meal. The tablets must be chewed.

CONSERVATION

Storage MyliconGas 40mg 50 chewable tablets - How to store MyliconGas 40mg 50 chewable tablets?

Store the medicine in the original package to protect the product from light and moisture.

WARNINGS

Warnings MyliconGas 40mg 50 chewable tablets - About MyliconGas 40mg 50 chewable tablets it is important to know that:

After a short period of treatment without appreciable results, consult your doctor. If symptoms persist, worsen, or if new symptoms appear or if constipation is prolonged, stop treatment and consult your doctor. Do not use if intestinal perforation or ileus is suspected. Important information about some of the excipients Mylicongas contains lactose . Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency e.g. galactosemia, or glucose-galactose malabsorption should not take this medicine. Mylicongas contains less than 1 mmol (23 mg) sodium per dose. It can therefore be considered essentially sodium-free.

INTERACTIONS

Interactions MyliconGas 40mg 50 chewable tablets - Which medicines or foods can modify the effect of MyliconGas 40mg 50 chewable tablets?

The simultaneous intake of SIMETICONE and laxatives based on mineral oils (paraffin) is not recommended, since the combination of these two products reduces their effectiveness.

SIDE EFFECTS

Like all medicines, MyliconGas 40mg 50 chewable tablets can cause side effects - What are the side effects of MyliconGas 40mg 50 chewable tablets?

Undesirable effects observed during treatment in clinical studies and integrated with those collected during post-marketing experience are listed in the table below according to the System Organ Class (using MedDRA terminology) and according to the following frequency: Very common ≥ 1/10; Common ≥ 1/100 and < 1/10; Uncommon ≥ 1/1,000 and < 1/100; Rare ≥ 1/10,000 and < 1/1,000; Very rare < 1/10,000.

Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at “https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse ”.

OVERDOSE

MyliconGas 40mg 50 chewable tablets Overdose - What are the risks of MyliconGas 40mg 50 chewable tablets in case of overdose?

No cases of overdose have been reported with the use of Mylicongas.

PREGNANCY AND BREASTFEEDING

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking MyliconGas 40mg 50 chewable tablets.

Pregnancy There are no adequate data on the use of Mylicongas in pregnant women, therefore it should not be used during pregnancy unless clearly necessary and after a risk/benefit assessment by the physician. Breastfeeding It is not known whether simethicone is excreted in human milk. The excretion of simethicone in human milk has not been studied in animals. A decision whether to continue/discontinue breastfeeding or to continue/discontinue therapy with simethicone should be made taking into account the benefit of breastfeeding for the child and of simethicone therapy for the woman. Consult a doctor before taking Mylicongas during pregnancy or breastfeeding.

DRIVING AND USE OF MACHINERY

Taking MyliconGas 40mg 50 chewable tablets before driving or using machines - Does MyliconGas 40mg 50 chewable tablets affect driving or using machines?

No effects on the ability to drive or use machines have been reported.